WWA
RLAY icon

Wingate Wealth Advisors’s Relay Therapeutics RLAY Stock Holding History

Wingate Wealth Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$20.6K – 347
2024
Q4 		$20.6K Buy
+5,000
New +$27.2K 0.02% 285

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Wingate Wealth Advisors's RLAY Position: Q1 2025 in Review

Wingate Wealth Advisors sold out of Relay Therapeutics (RLAY) in Q1 2025, closing a stake of 5,000 shares — an estimated $20.6K sold.

Wingate Wealth Advisors first reported a position in RLAY in Q4 2024 and held it in 1 quarter. The position peaked at $20.6K in Q4 2024. 207 funds tracked by Wall St. Rank hold RLAY as of Q1 2025.

  • Wingate Wealth Advisors reported no remaining Relay Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Wingate Wealth Advisors sold 5,000 Relay Therapeutics shares in Q1 2025, an estimated $20.6K.
  • Wingate Wealth Advisors first reported a position in Relay Therapeutics in Q4 2024 and held it in 1 quarter.
  • Wingate Wealth Advisors's Relay Therapeutics position peaked at $20.6K in Q4 2024.
  • 207 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2025.

Based on Wingate Wealth Advisors's 13F filing for Q1 2025, filed 24 Apr 2025.